Is there a generic for Mobic?

No approved generic versions of Mobic are currently tracked. 11 active patents remain.

How much cheaper is generic MELOXICAM?

Generic small-molecule drugs typically launch at 60-80% discount to the originator. After multiple manufacturers enter the market (12-24 months post-cliff), prices drop further to 85-95% below originator. Your insurance copay may not reflect the full savings — check the cash price too.

Are generics as effective as the brand?

For small-molecule drugs: yes. Generics are required to demonstrate bioequivalence — identical active ingredient, same dose, same route, same indication. Pharmacokinetic equivalence within tight bounds (±20% AUC + Cmax). Most patients can switch without clinical effect.

When did Mobic go generic?

Mobic has not yet gone fully generic. Patent timeline + exclusivity status is shown below.

Last reviewed 2026-06-10 · How we verify

Mobic generic

Complete generic competition for Mobic (MELOXICAM): 0 approved generics across manufacturers, 0 filed under FDA review. 11 active patents remain. Sourced from FDA Orange Book + USPTO.

0 approved generics 11 active patents

About Mobic

Mobic (MELOXICAM) — originally marketed by Boehringer Ingelheim. Class: Nonsteroidal Anti-inflammatory Drug [EPC]. First approved 2000-01-01.

Approved generic versions (0)

No approved generics tracked for this drug yet.

Originator patent timeline

Active patents (11)

2041-07-31 — 12263176 · Formulation · US
2040-07-19 — 12059423 · Compound · US
2039-03-08 — 11458145 · Method of Use · US
2039-03-08 — 10881663 · Method of Use · US
2035-03-31 — 9808468 · Method of Use · US
2035-03-31 — 9649318 · Formulation · US
2033-03-31 — 9526734 · Formulation · US
2030-08-31 — 8545879 · Formulation · US
2030-05-26 — 9974746 · Formulation · US
2030-05-26 — 10709713 · Method of Use · US
2030-05-26 — 11253478 · Formulation · US

Expired patents (0)

No expired patents tracked.

How small-molecule generic approval works

Generic versions of small-molecule drugs are approved by the FDA via the Abbreviated New Drug Application (ANDA) pathway under the Hatch-Waxman Act of 1984. Sponsors must demonstrate bioequivalence (pharmacokinetic equivalence within tight bounds) and identical chemical composition — no clinical trials in patients are required. Approval typically takes 18-24 months.

This is different from biosimilars for biologic drugs, which use the more complex 351(k) BLA pathway and typically achieve smaller (15-35%) discounts vs the originator. Small-molecule generics typically launch at 60-80% discount, dropping to 85-95% within 2 years.

Subscribe to generic updates

Mobic full drug profile
Biosimilar tracker (for biologic drugs)
Patent cliff tracker
Biosimilar vs generic — what's the difference?

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing